文献速递肺栓塞与肺血管病

阿那曲唑治疗肺动脉高压的随机双盲安慰剂对照试验

Pulmonary Hypertension and Anastrozole (PHANTOM): A Randomized, Double-Blind, Placebo-Controlled Trial.
PubMed 文献 · Am J Respir Crit Care Med · 2024-01-01

PHANTOM 是一项在7个中心开展的随机双盲安慰剂对照II期试验,纳入绝经后女性及男性肺动脉高压(PAH)患者,按1:1随机接受阿那曲唑1 mg每日口服或安慰剂。主要终点为6个月时6分钟步行距离(6MWD)较基线的变化,意向性分析显示两组无显著差异(安慰剂校正疗效-7.9米,95%CI -32.7至16.9,P=0.53),不良事件无差异。

要点

  • 阿那曲唑1 mg每日口服未改善PAH患者6个月6MWD。
  • 安慰剂校正6MWD变化为-7.9米(95%CI -32.7至16.9,P=0.53)。
  • 阿那曲唑安全,不良事件与安慰剂无差异。

核心结论

  • 在绝经后女性及男性PAH患者中,阿那曲唑对6个月6MWD无显著影响。
  • 阿那曲唑安全,未出现不良效应。

研究设计与样本

  • 随机、双盲、安慰剂对照II期临床试验,在7个中心开展。
  • 主要终点为6个月时6MWD较基线的变化,采用意向性分析,线性回归模型校正性别和基线6MWD。

主要发现

  • 6个月6MWD变化无显著差异:安慰剂校正疗效-7.9米(95%CI -32.7至16.9,P=0.53)。
  • 两组不良事件无差异。

关键数值与推荐

  • 阿那曲唑剂量1 mg每日口服。
  • 主要终点6个月6MWD变化,安慰剂校正疗效-7.9米(95%CI -32.7至16.9,P=0.53)。

临床怎么用

  • 不推荐使用阿那曲唑改善PAH患者6MWD。
  • 阿那曲唑在PAH患者中短期安全性良好,但无疗效支持。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: Inhibition of aromatase with anastrozole reduces pulmonary hypertension in experimental models. Objectives: We aimed to determine whether anastrozole improved the 6-minute-walk distance (6MWD) at 6 months in pulmonary arterial hypertension (PAH). Methods: We performed a randomized, double-blind, placebo-controlled phase II clinical trial of anastrozole in subjects with PAH at seven centers. Eighty-four postmenopausal women with PAH and men with PAH were randomized in a 1:1 ratio to receive anastrozole 1 mg or placebo by mouth daily, stratified by sex using permuted blocks of variable sizes. All subjects and study staff were masked. The primary outcome was the change from baseline in 6MWD at 6 months. By intention-to-treat analysis, we estimated the treatment effect of anastrozole using linear regression models adjusted for sex and baseline 6MWD. Assuming 10% loss to follow-up, we anticipated having 80% power to detect a difference in the change in 6MWD of 22 meters. Measurements and Main Results: Forty-one subjects were randomized to placebo and 43 to anastrozole, and all received the allocated treatment. Three subjects in the placebo group and two in the anastrozole group discontinued the study drug. There was no significant difference in the change in 6MWD at 6 months (placebo-corrected treatment effect, -7.9 m; 95% confidence interval, -32.7 to 16.9; P = 0.53). There was no difference in adverse events between the groups. Conclusions: Anastrozole did not show a significant effect on 6MWD compared with placebo in postmenopausal women with PAH and in men with PAH. Anastrozole was safe and did not have adverse effects. Clinical trial registered with www.clincialtrials.gov (NCT03229499).

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Kawut SM, Feng R, Ellenberg SS, et al. Pulmonary Hypertension and Anastrozole (PHANTOM): A Randomized, Double-Blind, Placebo-Controlled Trial. Am J Respir Crit Care Med. 2024. PMID: 38747680. doi:10.1164/rccm.202402-0371OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。